Filing Flows › CG Oncology (CGON) › R&D spending
CG Oncology (CGON) R&D spending by quarter
CG Oncology's R&D spending was $39.2M in Q3 2026 (third quarter 2026), -28% from Q2 2026. Over the last 7 quarters it ranged from $26.8M (Q4 2024) to $54.7M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $39.2M | -28% | +41% |
| Q2 2026 | $54.7M | +25% | — |
| Q1 2026 | $43.7M | +46% | +59% |
| Q4 2025 | $30.0M | +7% | +12% |
| Q3 2025 | $27.9M | +2% | — |
| Q1 2025 | $27.5M | +2% | — |
| Q4 2024 | $26.8M | — | — |
Q3 2026 at a glance
CG Oncology, Q3 2026: revenue $1.6M (-4% year over year), net loss $56.9M, operating cash flow −$47.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is CG Oncology's R&D spending?
CG Oncology's R&D spending was $39.2M in Q3 2026 (third quarter 2026), -28% from Q2 2026.
How has CG Oncology's R&D spending changed?
Over the last 7 quarters it ranged from $26.8M (Q4 2024) to $54.7M (Q2 2026).